Remix Therapeutics™ to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation Portfolio News / By Libby Nunan Remix Therapeutics™ to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation Read More »
Accent Therapeutics: Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics Portfolio News / By Libby Nunan Accent Therapeutics: Boehringer Ingelheim Obtains Novel Preclinical Oncology Program from Accent Therapeutics Read More »
Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer Portfolio News / By Libby Nunan Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer Read More »
Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS) Portfolio News / By Libby Nunan Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS) Read More »
A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer Portfolio News / By Libby Nunan A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer Read More »
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy Portfolio News / By Libby Nunan RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy Read More »
Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Portfolio News / By Libby Nunan Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Read More »
Judo Bio Named to The 2025 Endpoints 11: Broadening the reach of RNA drugs Portfolio News / By Libby Nunan Judo Bio Named to The 2025 Endpoints 11: Broadening the reach of RNA drugs Read More »
Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer Portfolio News / By Libby Nunan Atavistik Bio Expands Leadership Team with Appointment of Susan Pandya, M.D., as Chief Medical Officer Read More »
A2 Biotherapeutics to Present Data from Ongoing Phase 1/2 EVEREST-2 Study During the IASLC 2025 World Conference on Lung Cancer Portfolio News / By Libby Nunan A2 Biotherapeutics to Present Data from Ongoing Phase 1/2 EVEREST-2 Study During the IASLC 2025 World Conference on Lung Cancer Read More »
